Hormonal
Genetic variants that regulate circulating amino acid and lipid levels generally do not cause insulin resistance, suggesting that elevated amino acids are likely secondary markers of insulin resistance rather than causal drivers.
Genetic evidence suggests that high amino acid levels in your blood are likely a symptom of insulin resistance, not the cause. This means you don't need to restrict protein intake to fix insulin resistance. Instead, focus on lifestyle factors like exercise and healthy fats that improve how your body uses insulin.
None of the SNPs affecting the metabolites were associated with HOMA-IR (P > 0.05), with the exception of a variant in GCKR... Thus, these analyses on the direction of effect do not lend support to the notion of a causal role of amino acids in the development of insulin resistance.
Why this rating
Uses genetic variants as instrumental variables, a robust method for causal inference, but limited by the specific variants chosen and the young, healthy population.
Source
Metabolic Signatures of Insulin Resistance in 7,098 Young Adults
Peter Würtz et al. · Diabetes · 2012
DOI 10.2337/db11-1355
More from this paper
- Elevated circulating levels of branched-chain amino acids (Leu, Ile, Val) and aromatic amino acids (Phe, Tyr) are strongly associated with insulin resistance (HOMA-IR) in young, normoglycemic adults, with associations being significantly stronger in men and in women only when abdominally obese.Good
- Physical activity is inversely associated with insulin resistance and circulating metabolite levels, but these associations are largely attenuated when adjusting for HOMA-IR, suggesting physical activity improves insulin sensitivity directly rather than by lowering specific metabolite levels.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →